Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?

Nature Clinical Practice Oncology volume 1, pages 24–25 (2004)Cite this article

boxed-textCoombes RC et al. (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New Engl J Med 350: 1081–1092

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Paridaens R et al. (2003) Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer. Ann Oncol 14: 1391–1398

    Article  CAS  Google Scholar 

  2. Buzdar AU et al. (1998) Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase II trials. Cancer 83: 1142–1152

    Article  CAS  Google Scholar 

  3. Dombernowsky P et al. (1998) Letrozole, a new oral aramatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16: 453–461

    Article  CAS  Google Scholar 

  4. Baum M et al. (2003) Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: results of the ATAC (Arimidex, Tamoxifen Alone or in Combination) trial efficacy and safety update analyses. Cancer 98: 1802–1810

    Article  CAS  Google Scholar 

  5. Boccardo F et al. (2003) Anastrozole appears to be superior to tamoxifen in women already receiving adjuvant tamoxifen treatment. [abstract] Breast Cancer Res Treat 82 (Suppl): s6

    Google Scholar 

  6. Goss PE et al. (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349: 1793–1802

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Lisa Hutchinson, Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Editor of Nature Clinical Practice Oncology,

    Lisa Hutchinson

Authors
  1. Lisa Hutchinson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lisa Hutchinson.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hutchinson, L. Can exemestane improve adjuvant treatment for postmenopausal women with primary breast cancer?. Nat Rev Clin Oncol 1, 24–25 (2004). https://doi.org/10.1038/ncponc0021

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncponc0021

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing